GlassScriptPhysician profile
Larisa Meleks
NPI 1568567857
$1,914.31
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $989 · 2021: $76.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $225.32 | 2019-2021 | |
| Glaxosmithkline, LLC. | $193.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $159.33 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.61 | 2019-2020 | |
| Pfizer INC. | $131.06 | 2019-2021 | |
| Amgen INC. | $111.03 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $108.89 | 2019-2020 | |
| Lilly USA, LLC | $97.76 | 2019-2020 | |
| Radius Health, INC. | $91.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.73 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $69.59 | 2019-2020 | |
| Amarin Pharma, INC. | $63.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.66 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.62 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.48 | 2019-2020 | |
| Zyla Life Sciences, INC. | $23.16 | 2019 | |
| Abbvie INC. | $22.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.82 | 2019 | |
| Neurocrine Biosciences, INC. | $18.92 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.97 | 2021 | |
| Boston Scientific Corporation | $16.89 | 2019 | |
| Ibsa Pharma INC. | $15.63 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.45 | 2019 | |
| Aytu Biopharma, INC. | $12.89 | 2019 | |
| Fidia Pharma USA INC. | $8.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larisa Meleks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.